

THERMOGENESIS CORP. REQUESTS THE U.S. PATENT OFFICE TO RE-EXAMINE TWO ADDITIONAL PHARMASTEM CORD BLOOD STEM CELL PATENTS

RANCHO CORDOVA, CA (March 8, 2005) -- THERMOGENESIS CORP. (Nasdaq: KOOL) a manufacturer of sophisticated Cryogenic Systems for Cord Blood Banks today announced that it has requested that the United States Patent and Trademark Office ("PTO") re-examine patent No's 6,569,427 and 6,461,645 issued to PharmaStem Corporation.

This action follows the March 1, 2005 announcement by ThermoGenesis Corp. and the International Foundation NETCORD, the leading international network of public cord blood banks, that the PTO had reexamined PharmaStem Patent 5,192,553 (Patent '553) and rejected all its claims. These patents relate to the collection and preservation of umbilical cord and placental blood stem cells and the use of these cells in hematopoietic or immune reconstitution and the treatment of other diseases.

PharmaStem's patents have been attacked in the U.S. owing to the existence of prior art. In Europe, a single PharmaStem patent that consolidated all claims of both U.S. patents ('553 and 5,004,681 (Patent '681)) had all claims rejected, without further appeal, on April 10, 2003 as a result of actions brought on the same basis before the European Patent Office (EPO) by ThermoGenesis Corp., NETCORD and others. In Japan, the same prior art, filed in opposition by ThermoGenesis led to the rejection of all PharmaStem patent claims by the Japanese Patent Office on June 4, 1999.

Philip Coelho, Chairman and CEO of ThermoGenesis, said, "The organizations currently affected by this patent are our customers, not ThermoGenesis, and a favorable ruling to this request by the U.S. PTO could assist these stem cell banks and research organizations' abilities to conduct breakthrough research and offer life-saving treatments to patients without being encumbered by unwarranted royalty expenses. This request, which supports umbilical cord blood stem cell banking and assists the rapid and unencumbered proliferation of cord blood stem cell research, is in concert with our urging of the FDA to license this industry and set the highest possible standards of quality. We consider these actions to be vital to a field of medicine that is still very much in its infancy but has the potential to have a significant impact on the future treatment of many lethal or debilitating diseases."

About THERMOGENESIS CORP.

THERMOGENESIS CORP. is a leader in enabling technologies for cell therapeutics. The Company's technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company's BioArchive® System as a critical enabling technology for cryopreserving and archiving of cord blood stem cells for transplant, while its

CryoSeal® FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. The Company has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

More Information, Contact:
THERMOGENESIS CORP.
Philip Coelho: (916) 858-5100

###